Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2004-05-27
2008-12-16
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S141100, C424S143100, C424S144100, C530S387100, C530S388100, C530S388200, C530S388220
Reexamination Certificate
active
07465446
ABSTRACT:
The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
REFERENCES:
patent: 5811097 (1998-09-01), Allison et al.
patent: 5855887 (1999-01-01), Allison et al.
patent: 6051227 (2000-04-01), Allison et al.
patent: 6682736 (2004-01-01), Hanson et al.
patent: 2002/0039581 (2002-04-01), Carreno et al.
patent: 2002/0086014 (2002-07-01), Korman et al.
patent: WO-00/37504 (2000-06-01), None
patent: WO-01/14424 (2001-03-01), None
Beck et al., J. Clin. Oncol., 2006, 24: 2283-2289.
Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0, DCTD, NCI, NIH, DHHS, Mar. 31, 2003 (provided by Applicant).
Janik et al., “A Pilot Study Of MDX-010 After Vaccine Failure In Patients With Advanced Malignacy,” Blood, vol. 102, No. 11, p. 647A, Nov. 16, 2003.
Phan et al., “Cancer Regression And Autoimmunity Induced By Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade In Patients With Metastatic Melanoma,” Proceedings Of The National Academy Of Sciences Of USA, vol. 100, No. 14, pp. 8372-8377, Jul. 8, 2003.
International Search Report for PCT/US2004/016995, mailed May 10, 2005.
Van Elsas et al. Elucidating the autoimmune and antitumor effector mechanism of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. Aug. 20, 2001,V. 194, pp. 481-489, especially abstract, p. 482.
Chambers, Cynthia A., et al., “Lymphoproliferation in CTLA-4-Deficient Mice is Mediated by Costimulation-Dependent Activation of CD4+ T Cells”, Immunity, Dec. 1997, vol. 7, pp. 885-895.
Chambers, Cynthia A., et al., “Co-stimulation in T cell responses”, Curr. Opin. Immunol., 1997, vol. 9, pp. 396-404.
Hurwitz, Arthur A., et al., “CTLA-R blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma”, Proc. Natl. Acad. Sci., Aug. 1998, pp. 10067-10071.
Hurwitz, Arthur A., et al., “Immunotherapy of Primary Prostate Cancer in a Transgenic Model Using a Combination of CTLA-4 Blockade and Tumor Cell Vaccine”, Cancer Research, May 1, 2000, vol. 60, pp. 2444-2448.
Damle, Nitin K., et al., “Alloantigen-Specific Cytotoxic and Suppressor T Lymphocytes are Derived from Phenotypically Distinct Precursors”, The Journal of Immunology, Nov. 1983, vol. 131, No. 5, pp. 2296-2300.
Kearney, Elizabeth R., et al., “Antigen-dependent Clonal Expansion of a Trace Population of Antigen-Specific CD4+ T Cells in Vivo is Dependent on CD28 Costimulation and Inhibited by CTLA-41”, The Journal of Immunology, 1995, vol. 155, pp. 1032-1036.
Leach, Dana R., et al., “Enhancement of Antitumor Immunity by CTLA-4 Blockade”, Science, Mar. 22, 1996, vol. 271, pp. 1734-1736.
Lindsten, Tullia, et al., “Regulation of Lymphokine Messenger RNA Stability by a Surface-Mediated T Cell Activation Pathway”, Science, Apr. 21, 1989, vol. 244, pp. 339-343.
Luhder, Fred, et al., “Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA-4) Regulates the Unfolding of Autoimmune Diabetes”, J. Exp. Med., Feb. 2, 1998, vol. 187, No. 3, pp. 427-432.
Overwijk, Willem M., et al., “Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CDR+ T lymphocytes”, Proc. Natl. Acad. Sci., Mar. 1999, vol. 96, pp. 2982-2987.
Matsui, Toshihiro, et al., “Autoantibodies to T Cell Costimulatory Molecules in Systemic Autoimmune Diseases”, The Journal of Immunology, 1999, vol. 162, pp. 4328-4335.
Perrin, Peter J., et al., “CTLA-4 Blockade Enhances Clinical Disease and Cytokine Production During Experimental Allergic Encephalomyelitis 1,2”, The Journal of Immunology, vol. 157, pp. 1333-1336.
Rosenberg, Steven A., et al., “Vitiligo in Patients with Melanoma: Normal Tissue Antigens Can Be Targets for Cancer Immunotherapy”, Journal of Immunotherapy, vol. 19, No. 1, pp. 81-84.
Thompson, Craig B., et al., “CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines”, Proc. Natl. Acad. Sci., Feb. 1989, vol. 86, pp. 1333-1337.
Van Elsas, Andrea, et al., “Combination Immunotherapy of B16 Melanoma Using Anti-Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA-4) and Granulocyte/Macrophage Colony-Stimulating Factor (GM-CSF)-producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation”, J. Exp. Med., Aug. 2, 1999, vol. 190, No. 3, pp. 355-366.
Walunas, Theresa L., et al., “CTLA-4 Can Function as a Negative Regulator of T Cell Activation”, Immunity, Aug. 1994, vol. 1, pp. 405-413.
Lowy Israel
Nichol Geoffrey M.
Baker & Botts L.L.P.
Medarex Inc.
Ouspenski Ilia
LandOfFree
Surrogate therapeutic endpoint for anti-CTLA4-based... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Surrogate therapeutic endpoint for anti-CTLA4-based..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Surrogate therapeutic endpoint for anti-CTLA4-based... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4035438